Evidence map›Paper›PMID 20664684›Full record

ArticlePloS one2010

Acquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC).

Amanda Maestre, Carlos Muskus, Victoria Duque, Olga Agudelo, Pu Liu, Akihide Takagi, Francis B Ntumngia, John H Adams, Kim Lee Sim, Stephen L Hoffman and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Progress towards the development of aExpert review of vaccines · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Blood Groups in Infection and Host Susceptibility.Clinical microbiology reviews · 2015
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. The host genetic diversity in malaria infection.Journal of tropical medicine · 2012
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Amanda MaestreGrupo Salud y Comunidad, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
Carlos Muskus
Victoria Duque
Olga Agudelo
Pu Liu
Akihide Takagi
Francis B Ntumngia
John H Adams
Kim Lee Sim
Stephen L Hoffman
Giampietro Corradin
Ivan D Velez
Ruobing Wang
Universidad de Antioquia · COCenter for Infectious Disease Research · USUniversity of South Florida · USProtein Potential (United States) · USSanaria · USUniversity of Lausanne · CH

Funding

Immunological characterization of the P. vivax DBPR01AI064478 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI ADAMS, JOHN H · 2006 to 2023
$9.6M
Immune Response to P. vivax in Duffy (-) HumansR01AI057592 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI WANG, RUOBING · 2005 to 2010
$2.4M
NIAID NIH HHS R01 AI057592NIAID NIH HHS R01 AI064478
6 · The paper itself

Abstract

backgroundPolymorphism of the Duffy Antigen Receptor for Chemokines (DARC) is associated with susceptibility to and the severity of Plasmodium vivax malaria in humans. P. vivax uses DARC to invade erythrocytes. Individuals lacking DARC are 'resistant' to P. vivax erythrocytic infection. However, susceptibility to P. vivax in DARC+ individuals is reported to vary between specific DARC genotypes. We hypothesized that the natural acquisition of antibodies to P. vivax blood stages may vary with the host genotype and the level of DARC expression. Furthermore, high parasitemia has been reported to effect the acquisition of immunity against pre-erythrocytic parasites. We investigated the correlation between host DARC genotypes and the frequency and magnitude of antibodies against P. vivax erythrocytic stage antigens. METHODOLOGY/

findingsWe assessed the frequencies and magnitudes of antibody responses against P. vivax and P. falciparum sporozoite and erythrocytic antigens in Colombian donors from malaria-endemic regions. The frequency and level of naturally-acquired antibodies against the P. vivax erythrocytic antigens merozoite surface protein 1 (PvMSP1) and Duffy binding protein (PvDBP) varied with the host DARC genotypes. Donors with one negative allele (FY*B/FY*Bnull and FY*A/FY*Bnull) were more likely to have anti-PvMSP1 and anti-PvDBP antibodies than those with two positive alleles (FY*B/FY*B and FY*A/FY*B). The lower IgG3 and IgG1 components of the total IgG response may account for the decreased responses to P. vivax erythrocytic antigens with FY*A/FY*B and FY*B/FY*B genotypes. No such association was detected with P. falciparum erythrocytic antigens, which does not use DARC for erythrocyte invasion. CONCLUSION/SIGNIFICANCE: Individuals with higher DARC expression, which is associated with higher susceptibility to P. vivax infection, exhibited low frequencies and magnitudes of P. vivax blood-stage specific antibody responses. This may indicate that one of the primary mechanisms by which P. vivax evades host immunity is through DARC indirectly down-regulating humoral responses against erythrocytic invasion and development.

Indexed as

AnimalsAntibodies, ProtozoanAntigens, ProtozoanDuffy Blood-Group SystemEnzyme-Linked Immunosorbent AssayGenotypeHumansImmunoglobulin GImmunoglobulin MMalaria, VivaxMerozoite Surface Protein 1Plasmodium falciparumPlasmodium vivaxProtozoan ProteinsReceptors, Cell SurfaceACKR1 protein, humanAntibodies, ProtozoanAntigens, ProtozoanDuffy antigen binding protein, PlasmodiumDuffy Blood-Group SystemImmunoglobulin GImmunoglobulin MMerozoite Surface Protein 1Protozoan ProteinsReceptors, Cell Surface

Identifiers

PMID20664684
PMCPMC2896388
OpenAlexW2043743064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.